Last updated on August 2019

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.


Brief description of study

This is a phase 2 study to evaluate safety and efficacy of ABBV-105 and ABBV-599 (ABBV-105 plus upadacitinib) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid Arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs(bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to severely active RA and to define optimal dose for further development.

Clinical Study Identifier: NCT03682705

Find a site near you

Start Over

St. Jude Heritage /ID# 167379

Fullerton, CA United States
  Connect »

Valerius Medical Group /ID# 168123

Los Alamitos, CA United States
  Connect »

Millennium Research /ID# 167453

Ormond Beach, FL United States
  Connect »

BayCare Medical Group /ID# 170860

Saint Petersburg, FL United States
  Connect »

FL Med Clinic, PA /ID# 206279

Zephyrhills, FL United States
  Connect »

PRN of Kansas /ID# 167985

Wichita, KS United States
  Connect »

June DO, PC /ID# 170670

Lansing, MI United States
  Connect »

Arthritis Associates /ID# 209075

Hattiesburg, MS United States
  Connect »

Dhmc /Id# 167476

Lebanon, NH United States
  Connect »

Ocean Rheumatology /ID# 170673

Toms River, NJ United States
  Connect »

Health Research Oklahoma /ID# 167370

Oklahoma City, OK United States
  Connect »

McBk Sc /Id# 212575

Grodzisk Mazowiecki, Poland
  Connect »